Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for preventing or treating peripheral vascular disease using hepatocyte growth factor and stromal cell derived factor 1[alpha]

一种肝细胞生长因子、外周动脉疾病的技术，应用在基因治疗、药物组合、心血管系统疾病等方向，能够解决切割腿部、死亡等问题

Active Publication Date: 2017-08-18
HELIXMITH CO LTD
View PDF18 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the case of ischemic limb disease, the pain of being rotted is too severe, and the patient is given systemic anti-pain medication. If it develops to severe cases, it may lead to cutting of the leg or death. Therefore, it is necessary to fundamentally treat it. Protocols for these conditions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing or treating peripheral vascular disease using hepatocyte growth factor and stromal cell derived factor 1[alpha]
  • Composition for preventing or treating peripheral vascular disease using hepatocyte growth factor and stromal cell derived factor 1[alpha]
  • Composition for preventing or treating peripheral vascular disease using hepatocyte growth factor and stromal cell derived factor 1[alpha]

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Example 1. Experimental method for confirming the efficacy of the combination of hepatocyte growth factor and stromal cell-derived factor 1α on cell migration of human umbilical vein endothelial cells

[0082] Human umbilical vein endothelial cells were obtained from Lonza by collecting only vein endothelial cells from human umbilical cords and culturing them into single cells.

[0083] In order to confirm the hepatocyte growth factor (sequence 1 in the sequence listing, R&D systems Cat No.294-HG-025 / CF, U.S.) and the stromal cell-derived factor 1α (sequence 1 in the sequence listing) in the cell migration from human umbilical vein endothelial cells 4, the influence of R&Dsystems Cat No.350-NS-010 / CF, USA), and after coating Transwell (Corning, cat#3422) with 1% gelatin, inoculate 2×10 4 cells. To enable cell attachment, after culturing for one hour, each experimental group was arranged as follows (hepatocyte growth factor of 50ng / ml, stromal cell-derived factor 1α of ...

Embodiment 2

[0085] Example 2. Functional confirmation of the effect of the combination of hepatocyte growth factor and stromal cell-derived factor 1α on angiogenesis in Matrigel plug assay (Matrigel plug assay)

[0086] The effect of hepatocyte growth factor and stromal cell-derived factor 1α on angiogenesis was confirmed by matrigel plug experiment.

[0087] 5-week-old C57BL / 6 mice were divided into the following experimental groups (PBS, 300 ng of hepatocyte growth factor, 150 ng of hepatocyte growth factor + 150 ng of stromal cell-derived factor 1α). After placing 1 unit of heparin in 400 μl of basement membrane matrix (Corning, cat#356231), proteins belonging to the respective experimental groups were added. The basement membrane mixture prepared by this method was injected subcutaneously into the abdomen of mice. After 7 days, the implanted basement membrane matrix was isolated after sacrificing the mice, and the hemoglobin (hemoglobin) contained in each basement membrane was measur...

Embodiment 3

[0089] Example 3. Functional confirmation when hepatocyte growth factor and stromal cell-derived factor 1α were administered to a mouse model of lower limb ischemia (hindlimbischemia, HLI)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating peripheral vascular disease, the composition comprising, as an active ingredient: (a) hepatocyte growth factor (HGF) or an isoform thereof, and stromal cell derived factor 1[alpha] (SDF-1[alpha]); or (b) a polynucleotide encoding the HGF and a polynucleotide encoding the SDF-1[alpha]. The peripheral vascular disease (for example, ischemic limb disease) can be more effectively prevented or treated through the significant promotion of vascular endothelial cell migration and angiogenesis in the case of singly using the composition of the present invention than in the case of using HGF, an isoform thereof, SDF-1[alpha] or a polynucleotide codes a protein thereof.

Description

technical field [0001] The present invention relates to the present invention relates to comprising hepatocyte growth factor (Hepatocyte Growth Factor, HGF) or isomers of the above-mentioned hepatocyte growth factor and stromal cell derived factor 1α (Strom al Cell derived Factor1α, SDF-1α) or encoding the above-mentioned protein A pharmaceutical composition for preventing or treating peripheral arterial disease with the polynucleotide as an active ingredient. Background technique [0002] This patent application claims priority to Korean Patent Application No. 10-2014-0129361 filed with the Korean Intellectual Property Office on September 26, 2014, the disclosures of which are incorporated herein by reference. Cardiovascular disease is a disease in which blood vessels are narrowed or blocked due to reasons such as vascular sclerosis, and can be roughly divided into coronary artery disease (Coronary Artery Disease, CAD) and peripheral artery disease (Peripheral Artery Diseas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61K48/00A61P9/10
CPCA61K38/18A61K48/00A61K38/1833A61K38/195A61P9/00A61P9/10A61K48/0016
Inventor 郑在均李政勳李那妍
Owner HELIXMITH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com